The Growing Importance of Mitochondrial Toxicity Assessment in Drug Discovery and Development Agilent Case Study "Primum non nocere." First, do no harm. It's one of the guiding principles underlying the ethical practice of healthcare. More than that, it's a cautionary tale – one that resonates throughout the world of drug discovery and development. History has shown it's one thing to develop a drug that makes a positive impact on the medical condition of interest, it's quite another to ensure that a drug isn't also causing unintended health issues elsewhere. Mitochondrial toxicity is a case in point. Around the turn of the millennium, several drugs were brought to the market only to be quickly pulled again, in what turned out to be very high-profile failures for the companies i

Join for free to read